(166) Investigating the Impact of Concurrent Ototoxic Drugs on Cisplatin-Induced Ototoxicity in Pediatric Cancer

Poster Abstract: Background
Cisplatin is an effective chemotherapy used in the treatment of many pediatric malignancies, but it can cause ototoxicity, leading to irreversible bilateral sensorineural hearing loss in children. Incidence rates range from 22% to 70%, raising significant concerns for the cognitive and psychosocial development of young patients. The severity of hearing impairment correlates with cumulative cisplatin dosage, with contributing factors including age, cranial radiation, and concurrent use of ototoxic medications.

Objective
The aim of this study is to determine if there is an association between ototoxic drugs with cisplatin and hearing loss, as well as explore the potential protective effects of otoprotective drugs.

Methods
This retrospective study includes 175 patients ages 18 years and younger at the time of cancer diagnosis who received cisplatin at Rady Children’s Hospital between January 2013 and September 2023. We will assess the impact of concomitant ototoxic drugs using the CHANG scale for hearing assessment. Additionally, we will investigate the beneficial effects of otoprotective drugs, such as sodium thiosulfate or amifostine, on hearing outcomes.

Results
In progress

Discussion/Conclusion
In progress

References (must also be included in final poster): 1. Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012 Jul 15;59(1):144-8.

2. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355–360.

3. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649–655.

4. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588–8596.

5. Gurney JG, Tersak JM, Ness KK, et al. Children’s Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children’s Oncology Group. Pediatrics. 2007;120:e1229–e1236.